Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189985 | 0.89 | KDM1A (0.39) | KDM1AKDM1BKCNH2 | |
| SCHEMBL502648 | 0.78 | KDM1A (0.41) | KDM1AKDM1BKCNH2 | |
| SCHEMBL345490 | 0.76 | KDM1A (0.44) | KDM1AKDM1BKCNH2 | |
| SCHEMBL29365213 | 0.76 | KDM1A (0.44) | KDM1AKDM1BKCNH2 | |
| SCHEMBL505780 | 0.75 | KDM1A (0.48) | KDM1AKDM1BKCNH2 | |
| SCHEMBL345437 | 0.73 | KDM1A (0.43) | KDM1AKDM1BKCNH2 | |
| SCHEMBL28157241 | 0.69 | KDM1A (0.44) | KDM1AKDM1BKCNH2 | |
| SCHEMBL23885388 | 0.67 | ALDH1A1 (0.40) | KDM1AKDM1BKCNH2 | |
| SCHEMBL21597029 | 0.67 | KDM1A (0.43) | KDM1AKDM1BKCNH2 | |
| SCHEMBL1191944 | 0.67 | KDM1A (0.34) | KDM1AKDM1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198917-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2931731-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF BACE1 | Pfizer Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150231144-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-9045498-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140323474-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-10-30 | — | — | US | disclosed |
| US-8822456-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2014091352-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF BACE1 | PFIZER INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | KDM1A 3054/4885KDM1B 3603/4885KCNH2 445/4885 |
| US-20140323474-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | KDM1A 3054/4885KDM1B 3603/4885KCNH2 445/4885 |
| US-20150231144-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | KDM1A 3054/4885KDM1B 3603/4885KCNH2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.